Enlivex ( (ENLV) ) has issued an update.
Enlivex Therapeutics Ltd. has released its audited consolidated financial statements for the years ending December 31, 2024, and 2023. The report, audited by Yarel + Partners, confirms the company’s financial position and effective internal control over financial reporting. This transparency in financial reporting is crucial for maintaining investor confidence and supports Enlivex’s strategic positioning in the biotechnology sector.
More about Enlivex
Enlivex Therapeutics Ltd. is a company based in Israel, operating in the biotechnology industry. It focuses on developing innovative immunotherapy treatments for life-threatening diseases, with a particular emphasis on conditions related to immune system dysfunction.
YTD Price Performance: -17.74%
Average Trading Volume: 134,323
Technical Sentiment Signal: Strong Buy
Current Market Cap: $22.43M
Learn more about ENLV stock on TipRanks’ Stock Analysis page.